

Bronchial Hyperreactivity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/B1F440AC3B5EEN.html>

Date: May 2024

Pages: 131

Price: US\$ 6,499.00 (Single User License)

ID: B1F440AC3B5EEN

Abstracts

The 7 major bronchial hyperreactivity markets reached a value of US\$ 13.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 22.6 Billion by 2034, exhibiting a growth rate (CAGR) of 4.93% during 2024-2034.

The bronchial hyperreactivity market has been comprehensively analyzed in IMARC's new report titled "Bronchial Hyperreactivity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bronchial hyperreactivity, also known as airway hyperresponsiveness, refers to an exaggerated sensitivity of the airways in the lungs to various environmental triggers. Individuals suffering from this illness may exhibit hyperactive airways, which tend to narrow and constrict more easily than those of healthy people, often leading to respiratory symptoms. Some common indications associated with the disease include recurrent episodes of wheezing, coughing, shortness of breath, and chest tightness. These symptoms can differ in intensity and frequency and are often exacerbated by exposure to allergens, cold air, exercise, or respiratory infections. The diagnosis of bronchial hyperreactivity usually involves a combination of clinical history, physical examination, and specialized tests. One primary diagnostic tool is the bronchial challenge test, where a patient inhales increasing doses of a substance like methacholine, which can induce bronchoconstriction. A positive test, characterized by a significant decrease in lung function measured by spirometry after exposure, confirms the presence of the disease.

The escalating incidence of environmental pollutants and allergens, which can agitate the airways and induce inflammation, is primarily driving the bronchial hyperreactivity market. In addition to this, the inflating utilization of efficacious medications, such as corticosteroids, bronchodilators, leukotriene modifiers, etc., to manage and control the

inflammatory processes in patients is also creating a positive outlook for the market. Moreover, the widespread adoption of allergen avoidance strategies and lifestyle modifications, as they play a pivotal role in reducing triggers and improving overall respiratory health, is further bolstering the market growth. Apart from this, the rising usage of physical therapy and breathing exercises on account of their various benefits, such as enhancing lung function, promoting better breathing control, and mitigating bronchial hyperreactivity episodes, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of personalized medicine which encompasses the development of targeted therapies based on individual patient characteristics and genetic predispositions to address specific genetic markers associated with heightened bronchial sensitivity, is also augmenting the market growth. Furthermore, the increasing application of immunotherapy approaches, such as allergen-specific immunoglobulin E (IgE), that aim for desensitization and long-term symptom management is expected to drive the bronchial hyperreactivity market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the bronchial hyperreactivity market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bronchial hyperreactivity and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bronchial hyperreactivity market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bronchial hyperreactivity market
Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the bronchial hyperreactivity market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current bronchial hyperreactivity marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report: Market Insights

How has the bronchial hyperreactivity market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the bronchial hyperreactivity market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the bronchial hyperreactivity market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of bronchial hyperreactivity across the seven major markets?

What is the number of prevalent cases (2018-2034) of bronchial hyperreactivity by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of bronchial hyperreactivity by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with bronchial hyperreactivity across the seven major markets?

What is the size of the bronchial hyperreactivity patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of bronchial hyperreactivity?

What will be the growth rate of patients across the seven major markets?

Bronchial Hyperreactivity: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for bronchial hyperreactivity drugs across the

seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bronchial hyperreactivity market?

What are the key regulatory events related to the bronchial hyperreactivity market?

What is the structure of clinical trial landscape by status related to the bronchial hyperreactivity market?

What is the structure of clinical trial landscape by phase related to the bronchial hyperreactivity market?

What is the structure of clinical trial landscape by route of administration related to the bronchial hyperreactivity market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 BRONCHIAL HYPERREACTIVITY - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 BRONCHIAL HYPERREACTIVITY - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 BRONCHIAL HYPERREACTIVITY - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 BRONCHIAL HYPERREACTIVITY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 BRONCHIAL HYPERREACTIVITY - UNMET NEEDS

10 BRONCHIAL HYPERREACTIVITY - KEY ENDPOINTS OF TREATMENT

11 BRONCHIAL HYPERREACTIVITY - MARKETED PRODUCTS

- 11.1 List of Bronchial Hyperreactivity Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Nucala (Mepolizumab) - GlaxoSmithKline
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Tezspire (Tezepelumab) - Amgen/AstraZeneca
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Dulera (Mometasone/formoterol) - Merck & Co/Novartis
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Alvesco (Ciclesonide) - AstraZeneca/Covis Pharma/Takeda
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Breo Ellipta (Fluticasone furoate/vilanterol) - GSK/Innoviva
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 BRONCHIAL HYPERREACTIVITY - PIPELINE DRUGS

- 12.1 List of Bronchial Hyperreactivity Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Drug Name – Company Name
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13 BRONCHIAL HYPERREACTIVITY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14 BRONCHIAL HYPERREACTIVITY – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 BRONCHIAL HYPERREACTIVITY - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Bronchial Hyperreactivity - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Bronchial Hyperreactivity - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Bronchial Hyperreactivity - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Bronchial Hyperreactivity - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Bronchial Hyperreactivity - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Bronchial Hyperreactivity - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Bronchial Hyperreactivity - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Bronchial Hyperreactivity - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)

- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Bronchial Hyperreactivity - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Bronchial Hyperreactivity - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Bronchial Hyperreactivity - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Bronchial Hyperreactivity - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Bronchial Hyperreactivity - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Bronchial Hyperreactivity - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Bronchial Hyperreactivity - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Bronchial Hyperreactivity - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Bronchial Hyperreactivity - Access and Reimbursement Overview

16 BRONCHIAL HYPERREACTIVITY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 BRONCHIAL HYPERREACTIVITY MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 BRONCHIAL HYPERREACTIVITY MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Bronchial Hyperreactivity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/B1F440AC3B5EEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B1F440AC3B5EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

